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Mevalonate kinase deficiency impairs several aspects of the patient’s quality of life, 
thus early diagnosis and treatment are required to improve health-related quality of life 
(HRQOL). A 15-year-old patient with double heterozygosity for the mutations 1129G>A 
and 928G>A in MVK gene, heterozygosity for the mutation 2107C>A in CIAS1 gene and 
hyper-IgD syndrome phenotype, has been treated with anakinra with a reduction of 50% 
in the number of fever episodes per month, a reduction of 33% in the days of fever for 
each attack and normal blood tests in the intercritical phase. The RAND 36-Item Health 
Survey has been used for the assessment of HRQOL before and after the treatment with 
anakinra. The patient’s quality of life showed an overall improvement of 27%; results 
showed a better improvement in role limitations due to physical health (50%).
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INtRoDUCtIoN
Mevalonate kinase deficiency (MKD) is a rare autosomic recessive autoinflammatory disease 
caused by mutations of the MVK gene on chromosome 12q24, whose clinical spectrum ranges 
from hyper-IgD syndrome (HIDS) to lethal forms of mevalonic aciduria (MA) (1, 2). HIDS usually 
manifests before the age of 3 years, and it is characterized by recurrent and lifelong episodes of 
fever and inflammation lasting 5–7 days, transient arthritis, headache, abdominal pain, vomiting, 
hepatosplenomegaly, lymphadenopathy, and skin rashes (1). Fever attacks can occur in a cyclical 
pathway or be provoked by illnesses, injuries, and vaccinations; they are more frequent during child-
hood and decrease with age (2, 3). According to the International HIDS Database, the percentage 
of patients with more than 6 febrile attacks per year is about 90% in the first decade of life, 73% in 
the second decade of life and 50% after the age of 20 years; the percentage of patients with more 
than 12 febrile attacks per year is 44% in the first decade of life, 24% in the second decade of life, 
and 18% after the age of 20 years (4). Complete remission with age has never been reported (4). MA 
is also accompanied by psychomotor retardation, progressive visual impairment, cerebellar ataxia, 
seizures, myopathies, growth retardation, physical dysmorphisms (frontal bossing, hypertelorism, 
long eyelashes, triangular-shaped facies), cholestasis, and liver dysfunction (1, 2).
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It has been documented that MKD affects 300 people worldwide, 
with a higher prevalence in the Dutch population (about 1:200,000 
affected nationwide); HIDS is the most represented phenotype 
among affected people (2, 4). More than 120 sequence variants in 
MVK gene have been reported in patients affected by MKD; geno-
type–phenotype correlation is only partial, therefore additional 
genes are suspected to regulate genotype–phenotype correlation 
(2, 5, 6). In MKD, there is a depletion of 5-phosphomevalonic acid 
and its downstream products (geranyl pyrophosphate, farnesyl 
pyrophosphate, and geranylgeranyl pyrophosphate), which 
are implicated in protein prenylation (2). Cellular isoprenoid 
deficiency leads to the activation of monocytes, macrophages, 
RhoA, and Rac1, with subsequent IL-1β hypersecretion and 
proinflammatory cellular pyroptosis and apoptosis (2). HIDS is 
usually associated with high serum IgD (72–88% of patients); 
during flares, C-reactive protein and erythrocyte sedimentation 
rate are above the normal range, and neutrophil predominant leu-
kocytosis is frequent (2, 4, 7, 8). Urinary mevalonic acid is often 
elevated, and mevalonate kinase function is reduced (1.8–28% 
in HIDS patients, less than 0.5% in MA patients); 3% of HIDS 
patients have also high serum amyloid A (2).
Mevalonate kinase deficiency impairs several aspects of the 
patient’s quality of life (physical and social functioning, school, 
career, finance, emotion) with negative consequences on family 
life, independence, employment status, and daily activities, thus 
early diagnosis and treatment are required to improve health-
related quality of life (HRQOL) (3).
Currently, no therapies have been approved for MKD: col-
chicine and statins have performed poorly; non-steroidal anti-
inflammatory drugs and corticosteroids have also been used with 
some benefits (1–3). Colchicine provided a complete response in 
none of the patients from the Eurofever registry and in 2% of 
patients from a literature review by the Eurofever registry investi-
gators; partial response was achieved by 35% of patients from the 
Eurofever registry and 18% of patients from the literature review 
(9). Statins provided a complete response in none of the patients 
from the Eurofever registry and the literature review by the 
Eurofever registry investigators; partial response was achieved by 
27% of patients from the Eurofever registry and 32% of patients 
from the literature review (9). Non-steroidal anti-inflammatory 
drugs provided a complete response in 13% of patients from 
the Eurofever registry; partial response was achieved by 64% of 
patients from the Eurofever registry (9). Corticosteroids provided 
a complete response in 24% of patients from the Eurofever reg-
istry and in none of the patients from a literature review by the 
Eurofever registry investigators; partial response was achieved by 
67% of patients from the Eurofever registry and 63% of patients 
from the literature review (3, 9).
According to Ter Haar et  al., 59% of patients treated with 
etanercept, a TNF-α blocking agent, achieved a partial response, 
and only one complete response was reported (9). Complete 
response after etanercept was achieved by 22% of patients from a 
literature review by the Eurofever registry investigators, and 33% 
of patients from the same review reported a partial response (3, 9).
Infliximab provided no response among patients from the 
Eurofever registry (3, 9). Adalimumab provided a complete 
response in none of the patients from the Eurofever registry 
and in 33% of patients from a literature review by the Eurofever 
registry investigators; partial response was achieved by 50% of 
patients from the Eurofever registry and 33% of patients from the 
literature review (3, 9).
Tocilizumab, a monoclonal anti-IL-6 selective antibody, has 
also been promising, according to recent reports (2, 10). Liver 
transplantation or hematopoietic stem cell transplantation is 
good therapeutic option for refractory cases of MA (2, 11).
Anti-IL-1-targeting drugs are generating great interest among 
pediatric rheumatologists for inadequately controlled MKD 
(1, 3). Anakinra, a short half-life IL-1 receptor antagonist, has 
been used in both an “on-demand” and a daily prophylactic dos-
ing regimens (2, 12). It has been demonstrated that Anakinra is 
associated with decreased duration and severity of fever attacks 
even when given on-demand (≥50% reduction in duration to a 
maximum of 2 days of fever in 8 of 12 fever episodes), and its effec-
tiveness is higher within 24 h from the beginning of symptoms; 
conversely, no effects on the frequency of attacks were noted (2, 13). 
Furthermore, on-demand treatment with anakinra in HIDS 
patients is a good option to avoid the fever attacks in patients 
requiring vaccinations (2, 13). According to Rossi-Semerano 
et  al., 30% of patients reported full response with continuous 
administration of anakinra, and 70% of patients achieved a partial 
response (2, 12). Anakinra provided complete response in 22% of 
patients from the Eurofever registry and in 34% of patients from 
a literature review by the Eurofever registry investigators; partial 
response was achieved by 67% of patients from the Eurofever 
registry and 46% of patients from the literature review (3, 9).
It has also been demonstrated that canakinumab, a long 
half-life monoclonal anti-IL-1β selective antibody, is effective 
for inadeguately controlled MKD in dosing ranges from 2 
to 7  mg/kg every 4–8 weeks (1, 2, 9, 12). According to Rossi-
Semerano et  al., canakinumab provides full response in about 
50% of patients (12). As regards side effects, 90.2% of children 
treated with anakinra for an autoinflammatory disease presented 
at least one adverse effect versus 58.8% of children treated with 
canakinumab; this difference was mainly due to pain at injection 
site and injection-site reactions (12). Canakinumab provided 
complete response in 50% of patients from the Eurofever registry 
and in 67% of patients from a literature review by the Eurofever 
registry investigators; partial response was achieved by 50% of 
patients from the Eurofever registry and 33% of patients from 
the literature review (3, 9).
According to Galeotti et  al., partial clinical remission was 
achieved by seven of nine patients on anakinra and three of six 
patients on canakinumab; complete clinical remission was achieved 
by one of nine patients on anakinra and three of six patients on 
canakinumab (1). The 11 patients who were enrolled in the study 
by Galeotti et al. were aged 3–30 years; 8 of them suffered from 
HIDS and 3 of them were MA patients (1). According to Galeotti 
et  al., the number of days with fever decreased from 5 before 
treatment to 3 after anakinra and to 2 after canakinumab, and no 
changes were observed in the frequency of fever attacks (1). In the 
study by Galeotti et al., four patients were switched from anakinra 
to canakinumab to achieve a more convenient dosing schedule 
and to avoid injection-site reactions; canakinumab lowered the 
clinical score more than anakinra in three of the four patients (1).
tabLe 1 | Results of the RAND 36-Item Health Survey before and after the treatment with anakinra.
scale No. of items before anakinra after anakinra Improvement (%)
Physical functioning 10 950/1,000 95% 1,000/1,000 100% +5
Role limitations due to physical health 4 200/400 50% 400/400 100% +50
Role limitations due to personal or emotional problems 3 200/300 66.7% 300/300 100% +33.3
Energy/fatigue 4 240/400 60% 340/400 85% +25
Emotional well-being 5 320/500 64% 500/500 100% +36
Social functioning 2 150/200 75% 200/200 100% +25
Pain 2 110/200 55% 200/200 100% +45
General health 5 250/500 50% 425/500 85% +35
Total 35 2,420/3,500 69.1% 3,365/3,500 96.1% +27
FIGURe 1 | Improvement in each item after the beginning of the treatment 
with anakinra.
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Rilonacept provided a complete response in none of the patients 
from the Eurofever registry; one patient from the Eurofever registry 
reported a partial response after this treatment (3, 9).
We would like to draw attention to the administration of 
anakinra in a patient with MKD and its effects on HRQOL.
Case RepoRt
The patient was a 15-year-old Italian boy who was born from 
healthy, unrelated parents; he came to our attention because of 
fever associated with abdominal pain, vomiting, and headache. 
The patient had a history of recurrent fever attacks (38–39°C) 
since he was 3 months old. Each attack of fever lasted 4–5 days 
every 2 weeks and was accompanied by chills, fatigue, sore throat, 
lymphadenopathy, abdominal pain, and vomiting; folliculitis and 
aphthous stomatitis were often associated. These episodes were 
usually preceded by a well-recognized phase of malaise with 
headache and transient arthritis. In the intercritical periods, the 
patient was totally asymptomatic. He had already been admitted 
six times because of prolonged fever and diagnosed as tonsillitis 
for two times, acute otitis media, sinusitis, and pneumonia for 
two times. The patient was usually bedridden during severe flares; 
his life was unpleasant: the recurrent fever attacks limited his 
activities and relationships and interfered with the development of 
autonomy during childhood because of the increased dependency 
on caregivers and the decreased participation in peer and school 
activities. Recurrent severe flares made the high school graduation 
unachievable for our patient; his mother had very limited career 
options, and finally she lost her work. Furthermore, a psychologi-
cal follow-up was even required for the patient and his caregivers.
On clinical examination, the patient presented fever (38.4°C), 
sore throat, aphthous stomatitis, cervical lymphadenopathy, 
enlarged tonsils, and hepatomegaly. His height was 170 cm (50th 
centile), and weight was 53  kg (10th–25th centile). His blood 
pressure was 109/71 mmHg, heart rate was 108 per minute, and 
respiratory rate was 20 per minute.
Laboratory findings were unremarkable except for elevated 
inflammatory indexes (erythrosedimentation rate 115  mm/h, 
C-reactive protein 182 mg/dL, serum amyloid A 40 mg/L) and 
high levels of serum immunoglobulins D (564 IU/mL); all bacte-
rial cultures were negative, and urinalysis was normal. No abnor-
malities were found on chest X-ray, abdominal ultrasound, and 
echocardiogram. The diagnosis of HIDS was made on the basis 
of a double heterozygosity for the MVK mutations 1129G>A and 
928G>A; the patient also showed heterozygosity for the mutation 
2107C>A in CIAS1 gene.
The periodic symptomatology of the patient has never less-
ened despite the administration of steroids, non-steroidal anti-
inflammatory drugs and antibiotics. Thus, we decided to start 
the treatment with daily subcutaneous injections of anakinra at 
a dosage of 1 mg/kg. The first injection of anakinra was followed 
by a clinical and laboratoristic improvement, thus the patient 
continued the daily administration of anakinra. After a follow-up 
of 24 months, we have noticed a reduction of 50% in the number 
of fever episodes per month and a reduction of 33% in the days of 
fever for each attack. Blood tests became normal in the intercriti-
cal phase, differently from the period in which anakinra was not 
administered.
The RAND 36-Item Health Survey is a 8-item questionnaire 
that explores physical functioning, bodily pain, role limitations 
due to physical health problems, role limitations due to personal 
or emotional problems, emotional well-being, social functioning, 
energy/fatigue, and general health perceptions; it also presents a 
single item about the perception of change in health (14). This 
questionnaire has been used for the assessment of HRQOL in our 
patient before and after the treatment with anakinra; in our case, 
the item about the perception of change in health was excluded.
Results showed a better improvement in role limitations due to 
physical health and in pain (50 and 45%, respectively); improvement 
in emotional well-being, in general health, and in role limitations due 
to personal or emotional problems was 36, 35, and 33.3%, respec-
tively. Improvement in energy/fatigue and in social functioning was 
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similar (25% for both the items). Improvement in physical function-
ing was only 5% as the patient started from 95% and reached 100% 
in physical functioning after the beginning of the treatment with 
anakinra. Overall, the patient registered an improvement of 27% in 
HRQOL after the beginning of the treatment with anakinra. Results 
are showed in Table 1; Figure 1 shows the improvement in each 
item after the beginning of the treatment with anakinra.
CoNCLUsIoN
Anakinra has been demonstrated to reduce the number of fever 
episodes per month and the days of fever for each attack and to 
improve HRQOL; improvement was more evident in the field of 
role limitations due to physical health, in pain, and in emotional 
well-being. In sum, our case confirms the efficacy of anakinra in 
MKD and points out its efficacy in giving the patient an acceptable 
quality of life. Positive effects of anakinra on psychological well-
being are also pointed out that they are very important for the 
patient, considering that MKD is chronic disease. Interestingly, 
our patient was the first to achieve a reduction in the frequency 
of fever attacks after anakinra.
Furthermore, the patient showed a double heterozygosity for 
the MVK mutations 1129G>A and 928G>A. 1129G>A (V377I) 
is the most frequently occurring mutation in MVK gene with 
an estimated allele frequency of 1:153 (15). The V377I allele has 
been found exclusively in HIDS patients; however, individuals 
homozygous for this allele may not be symptomatic (15). Based 
on the distinct phenotype (symptomatic versus asymptomatic) 
of two sibs carrying the same homozygous 1129G>A mutation, 
Messer et al. suggest the existence of modifiers loci controlling 
the penetrance of HIDS (16). The G-to-A transition at nucleotide 
928 (928G>A), resulting in a valine-to-methionine substitution 
at codon 310 (V310M), is a missense pathogenic variant that has 
been observed in association with MA (17, 18). The present case 
report describes a double heterozygous patient for the MVK muta-
tions 1129G>A and 928G>A, which showed an HIDS phenotype.
Our patient also showed heterozygosity for the mutation 
2107C>A in CIAS1 gene, which encodes for a protein called cry-
opyrin; this gene is also known as NLRP3 (NOD-like receptor 3) 
(19). Mutations of CIAS1 gene are found in about 70% of patients 
with a cryopyrin-associated periodic syndromes (CAPS) phe-
notype (19). Molecular analysis of CIAS1 gene was performed 
because recurrent fever attacks made us suspect a CAPS pheno-
type in our patient. CAPS include three autosomal dominant dis-
orders: familial cold autoinflammatory syndrome, Muckle–Wells 
syndrome, and chronic infantile neurological cutaneous and 
articular syndrome (CINCA) (19). Cryopyrin is a protein of the 
inflammasome; mutations in CIAS1 gene are associated with gain 
of function of cryopyrin and enhanced production of IL-1β (19). 
The treatment of CAPS is mainly based on subcutaneous anakinra 
at a starting dosage of 1 mg/kg/day; good results have also been 
achieved with canakinumab and rilonacept (19–22). According 
to Aksentijevich et  al., among patients with CAPS phenotype, 
the Q703K (2107C>A) missense change had an estimated allele 
frequency of 0.04; among Caucasian controls, the 2107C>A 
nucleotide transversion had an estimated allele frequency of 
0.05 (23). Aksentijevich et al. concluded that the allele Q703K is 
unlikely to be pathogenic because of the similar allele frequency 
in patients and control cohorts (0.04 versus 0.05, P = 0.84) (23). 
Aksentijevich et  al. demonstrated that there is a lack of clear 
genotype/phenotype correlation for many mutations of CIAS1 
gene and mutational severity is not correlated with mutation 
cluster position, the specific residue mutated or conservation 
among CIAS1 orthologs, therefore other genetic factors should 
be involved in determining the disease severity (23). Finally, the 
presence of the mutation 2107C>A in CIAS1 gene in our patient 
confirms that the allele Q703K is unlikely to be pathogenic.
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